Thr373
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Thr373  -  RMP (human)

Site Information
KRKRKNstGsGHsAQ   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 6208582

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 2 , 3 , 4 )
Disease tissue studied:
lung cancer ( 3 ) , non-small cell lung cancer ( 2 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Treatments:
metastatic potential ( 3 )

References 

1

Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71
23186163   Curated Info

2

Rikova K (2012) CST Curation Set: 16150; Year: 2012; Biosample/Treatment: cell line, H3255/iressa; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST], LXRXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXXS*/T*) (110B7E) Rabbit mAb Cat#: 9614 Phospho-AMPK Substrate Motif [LXRXX(pS/pT) MultiMab(TM) Rabbit mAb mix Cat#: 5759
Curated Info

3

Wang YT, et al. (2010) An informatics-assisted label-free quantitation strategy that depicts phosphoproteomic profiles in lung cancer cell invasion. J Proteome Res 9, 5582-97
20815410   Curated Info

4

Zhou J (2009) CST Curation Set: 7604; Year: 2009; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info